Conferences
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Sonpavde provides an overview of a phase I/II trial in progress on V940 (mRNA-4157) for resected high-risk MIUC.
Drs. Roupret and Houede dissect their research on the safety and efficacy of durvalumab with NAC for operable high-risk UTUC.
PRO data suggest tivozanib monotherapy maintained quality of life in patients with RCC that progressed after ICI therapy.
The findings from the substudy point to durable antitumor activity for the lenvatinib + belzutifan combination.
Dr. Albiges details the final results of COSMIC-313, highlighting the effectiveness of cabo plus nivo/ipi for aRCC.
Drs. Xu and Joyce break down the evaluation of circulating KIM-1 as a prognostic and predictive biomarker in advanced RCC.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
Newly presented research on the CALGB-90203 (PUNCH) and NRG/RTOG-0521 trials are discussed.
Dr. Kitamura shares the differences observed between the JAVEMACS and JAVELIN Bladder 100 patient cohorts.
Dr. Hassanzadeh elaborates on the benefits of MDT for patients with progressive or de novo disease.
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.